公开(公告)号：US10588973B2

公开(公告)日：2020-03-17

申请号：US15960392

申请日：2018-04-23

申请人： MEDRx CO., LTD

发明人： Yasushi Miwa ,  Hidetoshi Hamamoto ,  Naoya Akazawa

IPC分类号： A61K47/12 ,  A61K9/00 ,  A61K9/70 ,  A61K31/433 ,  A61K31/485

摘要： The embodiments provide a percutaneous absorption composition for a basic medicament having improved transdermal absorbability. The percutaneous absorption composition comprises a sorbic acid and/or a metal sorbate as a percutaneous absorption promotor. The molar ration of the sorbic acid and/or the metal sorbate to the basic medicament is 0.5-2.5. The composition of the present disclosure may further comprise a basic component.

公开(公告)号：US20240108578A1

公开(公告)日：2024-04-04

申请号：US18276937

申请日：2022-02-10

申请人： MEDRx Co., Ltd.

发明人： Tatsuhiro Ishida ,  Noboru Tatsumi ,  Takashi Nakae ,  Yasushi Miwa ,  Hidetoshi Hamamoto

IPC分类号： A61K9/00 ,  A61K38/26 ,  A61K47/12 ,  A61K47/18 ,  A61K47/32 ,  A61K47/38

CPC分类号： A61K9/0095 ,  A61K38/26 ,  A61K47/12 ,  A61K47/18 ,  A61K47/32 ,  A61K47/38

摘要： The present invention provides a composition comprising an ionic liquid and a poorly absorbable drug, wherein the ionic liquid is prepared from an anion and a cation, the anion is an organic acid having 3 to 7 carbon atoms, and the cation is selected from the group consisting of arginine, meglumine, trometamol and diethanolamine, which remarkably improves the absorbability of the poorly absorbable drug.

公开(公告)号：US11903939B2

公开(公告)日：2024-02-20

申请号：US16282215

申请日：2019-02-21

申请人： MEDRx Co., LTD

发明人： Hidetoshi Hamamoto ,  Yasushi Miwa ,  Katsuhiro Yamanaka ,  Noboru Tatsumi

IPC分类号： A61K31/485 ,  A61K9/70 ,  A61F13/02 ,  A61F13/00 ,  A61K31/4468 ,  A61M35/00

CPC分类号： A61K31/485 ,  A61F13/00063 ,  A61F13/023 ,  A61F13/0289 ,  A61K9/7084 ,  A61K31/4468 ,  A61M2205/273

摘要： The present disclosure provides a patch preparation having features that prevent accidental use. In some embodiments, a patch preparation containing a plaster on a support, wherein the plaster comprises a solvent that is a combination of ethyl acetate and n-heptane. The patch preparation can lose its adhesion after the plaster is exposed to air and at least some of the solvent has evaporated, or if the patch is removed from the skin. This feature prevent the used patch from being applied to the skin again, and can prevent accidental use. A method of forming a patch preparation is also disclosed.

公开(公告)号：US20220370376A1

公开(公告)日：2022-11-24

申请号：US17769944

申请日：2020-10-14

申请人： MEDRX CO., LTD.

发明人： Yasushi Miwa ,  Hidetoshi Hamamoto

IPC分类号： A61K9/70 ,  A61K47/34 ,  A61K31/433 ,  A61K47/10 ,  A61K47/32 ,  A61K47/02 ,  A61K47/14

摘要： The present disclosure, for example, can include a laminated type patch A, comprising a release layer 1, a drug layer 2, a drug support layer 3 having elasticity, an adhesive layer 4, and an adhesive support layer 5 laminated in this order, wherein the outer edges of the release layer, the adhesive layer, and the adhesive support layer are all outside the outer edges of both the drug layer and the drug support layer; wherein the portion surrounded by the outer edges of the drug layer and the drug support layer, and the inner sides of the release layer and the adhesive layer has a space; and wherein the cross-sectional area of the space is 0.3 mm2 or more, at least when cut along the longitudinal centerline and the transverse centerline on the plane surfaces of the drug layer and the drug support layer.

公开(公告)号：US20200171156A1

公开(公告)日：2020-06-04

申请号：US16782988

申请日：2020-02-05

申请人： MEDRx CO., LTD

发明人： Yasushi Miwa ,  Hidetoshi Hamamoto ,  Naoya Akazawa

IPC分类号： A61K47/12 ,  A61K31/433 ,  A61K31/485 ,  A61K9/70

摘要： The embodiments provide a percutaneous absorption composition for a basic medicament having improved transdermal absorbability. The percutaneous absorption composition comprises a sorbic acid and/or a metal sorbate as a percutaneous absorption promotor. The molar ration of the sorbic acid and/or the metal sorbate to the basic medicament is 0.5-2.5. The composition of the present disclosure may further comprise a basic component.

公开(公告)号：US20240024444A1

公开(公告)日：2024-01-25

申请号：US18019871

申请日：2021-08-06

申请人： MEDRx Co., Ltd.

发明人： Yasushi Miwa ,  Hidetoshi Hamamoto ,  Tatsuhiro Ishida

IPC分类号： A61K39/00 ,  A61K39/39 ,  A61K47/12 ,  A61K47/18 ,  A61P35/00 ,  A61K9/70

CPC分类号： A61K39/001153 ,  A61K39/39 ,  A61K47/12 ,  A61K47/18 ,  A61P35/00 ,  A61K9/7023 ,  A61K2039/55577 ,  A61K2039/55561 ,  A61K2039/54

摘要： The present invention is to provide a combined preparation comprising a first preparation for transdermal administration comprising an antigenic peptide and an aliphatic carboxylic acid-based ionic liquid, and a second preparation for transdermal administration comprising an adjuvant and an aliphatic carboxylic acid-based ionic liquid, enhances the skin permeability of an antigenic peptide and an adjuvant and thus effectively enhances the effect of activating the immune response with the antigenic peptide by the use of the adjuvant.

公开(公告)号：US20180236082A1

公开(公告)日：2018-08-23

申请号：US15960392

申请日：2018-04-23

申请人： MEDRx CO., LTD

发明人： Yasushi Miwa ,  Hidetoshi Hamamoto ,  Naoya Akazawa

IPC分类号： A61K47/12 ,  A61K9/70 ,  A61K31/433 ,  A61K31/485

摘要： The embodiments provide a percutaneous absorption composition for a basic medicament having improved transdermal absorbability. The percutaneous absorption composition comprises a sorbic acid and/or a metal sorbate as a percutaneous absorption promotor. The molar ration of the sorbic acid and/or the metal sorbate to the basic medicament is 0.5-2.5. The composition of the present disclosure may further comprise a basic component.

公开(公告)号：US20170056502A1

公开(公告)日：2017-03-02

申请号：US15279210

申请日：2016-09-28

申请人： MEDRx CO., LTD

发明人： Yasushi Miwa ,  Hidetoshi Hamamoto ,  Naoya Akazawa

IPC分类号： A61K47/12 ,  A61K9/70 ,  A61K47/02 ,  A61K47/18 ,  A61K31/433 ,  A61K31/485

CPC分类号： A61K47/12 ,  A61K9/7053 ,  A61K31/433 ,  A61K31/485

摘要： The embodiments provide a percutaneous absorption composition for a basic medicament having improved transdermal absorbability. The percutaneous absorption composition comprises a sorbic acid and/or a metal sorbate as a percutaneous absorption promotor. The molar ration of the sorbic acid and/or the metal sorbate to the basic medicament is 0.5-2.5. The composition of the present disclosure may further comprise a basic component.

摘要翻译： 实施方案提供了具有改善的经皮吸收能力的碱性药物的经皮吸收组合物。 经皮吸收组合物包含作为经皮吸收促进剂的山梨酸和/或金属山梨酸酯。 山梨酸和/或金属山梨酸盐对碱性药物的摩尔比为0.5-2.5。 本公开的组合物还可以包含基本组分。

公开(公告)号：US20230167448A1

公开(公告)日：2023-06-01

申请号：US17916060

申请日：2021-04-02

申请人： MEDRx Co., Ltd.

发明人： Yasushi Miwa ,  Hidetoshi Hamamoto ,  Tatsuhiro Ishida

IPC分类号： C12N15/113 ,  A61P17/06

CPC分类号： C12N15/1136 ,  A61P17/06 ,  C12N2310/11 ,  C12N2310/30

摘要： The present invention provides a novel siRNA specifically inhibiting the expression of IL-23 and a pharmaceutical composition comprising the siRNA, specifically a double stranded RNA comprising a sense strand and an antisense strand wherein each strand has 19 to 30 nucleotides and comprises the base sequence selected from SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6 or a complementary base sequence thereof and a pharmaceutical composition comprising the double stranded RNA.

公开(公告)号：US11559519B2

公开(公告)日：2023-01-24

申请号：US16965758

申请日：2019-01-31

申请人： MEDRx Co., Ltd.

发明人： Yasushi Miwa ,  Hidetoshi Hamamoto ,  Naoya Akazawa ,  Takahiro Tanimoto

IPC分类号： A61K31/433 ,  A61K9/70 ,  A61K47/12

摘要： An object of the present invention is to provide a method for the treatment of a patient suffering from spasticity comprising administering to said patient a modified release dosage form comprising tizanidine or a pharmaceutically acceptable salt thereof.
The present invention relates to a method of administering a transdermal patch preparation comprising tizanidine or a pharmaceutically acceptable salt thereof to a subject in need thereof, wherein the transdermal patch preparation releases about 4 mg to about 36 mg of tizanidine or a pharmaceutically acceptable salt thereof for at least about 24 hours.